CompletedPhase 1NCT00598169
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AIDS Malignancy Consortium
- Principal Investigator
- Erin G. Reid, MDUniversity of California, San Diego
- Intervention
- rituximab(biological)
- Enrollment
- 23 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2007 – 2014
Study locations (17)
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
- University of California at Davis Center for Aids Research and Education Services, Sacramento, California, United States
- University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
- Emory Winship Cancer Institute, Atlanta, Georgia, United States
- Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
- Northwestern Cancer Center, Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia, Philadelphia, Pennsylvania, United States
- Thomas Street Health Center, Houston, Texas, United States
- +2 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · The Emmes Company, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00598169 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital